Involvement of Differential Relationship between HCV Replication and Hepatic PRR Signaling Gene Expression in Responsiveness to IFN-Based Therapy

Table 1

Patient characteristics regarding virologic response to PEG-IFN and ribavirin.

Characteristics	Response at week 12		Response at week 24		Posttreatment response
	Yes	No	Yes	No	Yes	No
No.	14	31	26	14	22	16
Sex, M/F (% men)	10/4 (71)	19/12 (61)	17/9 (65)	9/5 (64)	16/6 (73)	9/7 (56)
Age	52±11	59±10	55±11	59±10	52 ± 10^a	61±8
Previous IFN therapy, 𝑛 (%)	3 (21)	15 (48)	7 (27)	7 (50)	5 (23)^a	9 (56)
ALT (IU/L)	85±63	77±41	83±55	68±31	89±57	60±29
Serum HCV RNA (log IU/mL)	6.1±0.6	6.2±0.4	6.2±0.5	6.2±0.3	6.2±0.5	6.2±0.3
Liver inflammatory score	7.0±2.1	7.0±2.5	7.0±2.1	6.7±2.9	7.1±2.3	6.6±2.7
Liver fibrosis score	1.7±1.2	2.2±1.1	1.9±1.2	2.2±1.1	1.8±1.2	2.4±1.0

Variables are presented as mean ± SD.
aStatistically significant difference 𝑃<0.05 between responders and nonresponders.